Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study.

ABSTRACT:

Background

The measurement of CMV specific cellular immunity in organ transplant recipients could contribute additional acuity to serology based, CMV infection risk stratification, facilitating optimisation of immunosuppression and anti-viral prophylaxis.

Methods

A pilot study of renal transplant recipient (RTR's) responses in the T-SPOT.CMV ELISPOT based assay. 108 RTR's were recruited 3 months post-transplantation, immediately prior to the cessation of stratified anti-viral prophylaxis, used in recipients from seropositive donors. RTR's were monitored for CMV viremia and disease. Cellular responses to peptides derived from CMV IE1 and pp65 were measured, using the T-SPOT.CMV assay.

Results

At recruitment, no CMV specific cellular immunity was detected by T-SPOT.CMV

SUBMITTER: Chanouzas D 

PROVIDER: S-EPMC5860728 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature